Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Enantone

ApprovedSmall molecule

Enantone is one of 30 small molecule programs targeting Adenomyosis. It is currently in Approved.

2

Indications

3

Total Trials

0

Active Trials

29

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenomyosisActive, not recruiting

Central Precocious PubertyActive, not recruiting

AdenomyosisApproved

Active, not recruiting

Central Precocious PubertyPreclinical

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Adenomyosis

#DrugCompanyPhaseTrials

Bayer Aspirin

Femara

Zoladex

TTerSera Therapeutics LLC

Ofev

Boehringer Ingelheim

Prometrium

Gnrh Agonist

Johnson & Johnson

Mifeprex

Enantone

Gnrh Analog

MMemorial Sloan Kettering Cancer Center

Ulipristal Acetate

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adenomyosis1 trial

Adenomyosis and ART

Unknown status·AAzienda Ospedaliero-Universitaria di Modena·Phase 4·NCT05937490·500 enrolled

MPA1 trial

Comparison of a Novel Leuprolide With Market Leuprolide

Unknown status·LLee's Pharmaceutical Limited·N/A·NCT03662958·48 enrolled

Central precocious puberty1 trial

A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

Completed· Takeda logo

Takeda··NCT02993926·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Enantone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Enantone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Enantone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Takeda

Related News